Regeneron Pharmaceuticals | REGN - Current Liabilities


Regeneron Pharmaceuticals reported $6.2B in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Agenus USD 231.82M 17.42M Jun/2026
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
Astellas Pharma JPY 1.1T 134.96B Sep/2026
AstraZeneca USD 31.27B 286M Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
J&J USD 55.46B 562M Sep/2026
Kyowa Hakko Kirin JPY 150.28B 32.11B Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Moderna USD 2.03B 506M Sep/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Novartis USD 32.52B 777M Sep/2026
Novartis USD 32.52B 1.15B Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Teva Pharmaceutical Industries USD 15.42B 221M Sep/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
United Therapeutics USD 624.3M 16.5M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026